Vise Technologies Inc. Has $1.46 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Vise Technologies Inc. lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 33.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,582 shares of the medical research company's stock after acquiring an additional 1,406 shares during the quarter. Vise Technologies Inc.'s holdings in Amgen were worth $1,455,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Capital World Investors boosted its position in shares of Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after buying an additional 6,029,058 shares during the period. Norges Bank bought a new stake in Amgen during the 4th quarter valued at $1,541,991,000. Capital International Investors raised its stake in Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock valued at $3,182,843,000 after acquiring an additional 3,495,503 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Amgen in the fourth quarter worth $401,913,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AMGN shares. Piper Sandler dropped their target price on Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Morgan Stanley reaffirmed an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Mizuho boosted their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Finally, UBS Group reissued a "neutral" rating and issued a $315.00 price target (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Amgen currently has a consensus rating of "Hold" and an average target price of $309.22.

Amgen Stock Up 1.3%

Shares of Amgen stock traded up $3.72 during midday trading on Thursday, hitting $282.12. The company's stock had a trading volume of 913,334 shares, compared to its average volume of 2,794,056. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a market capitalization of $151.70 billion, a P/E ratio of 37.35, a PEG ratio of 2.63 and a beta of 0.51. The stock has a 50-day simple moving average of $284.48 and a 200-day simple moving average of $285.76.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the prior year, the business earned $3.96 EPS. The business's revenue for the quarter was up 9.4% on a year-over-year basis. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.37%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is currently 86.86%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.